

HYBRIGENICS

Press release

Hybrigenics SA brings its fee-for-service activities to a fully owned subsidiary, Hybrigenics Services SAS

Paris, 05 July 2010 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces that its fee-for-service scientific activities are brought to a fully-owned subsidiary named Hybrigenics Services SAS (“Société Anonyme Simplifiée”).

Hybrigenics Services SAS will focus on further growth of fee-for-service businesses

The Annual General Meeting on June 25, 2010 approved the creation of a subsidiary called Hybrigenics Services SAS, fully-owned by Hybrigenics SA. This business generated €3.27 million of revenue in 2009 (up 8% from the prior year) and operates independently within Hybrigenics SA. Hybrigenics Services SAS will enjoy greater independence as a separate profit center, especially in terms of access to working capital to finance an aggressive marketing and sales strategy and to fuel organic and/or potential external growth.

Hybrigenics SA will remain focussed on proprietary pharmaceutical R&D

The Phase IIa clinical development study of inecalcitol produced very promising results in terms of tolerance and presumption of efficacy in hormone-refractory prostate cancer. The maximum tolerated oral dose of inecalcitol is extremely high: 4 milligram per day. The response rate to the combination treatment with Taxotere now reached 84%: 38 patients out of 45 evaluable patients on prostate specific antigen (PSA) decline within 3 months. Patient enrolment has been completed up to 54 patients; the last treatments will take place in September. Given this excellent tolerance, Hybrigenics SA is considering testing oral inecalcitol in other potential indications, such as severe psoriasis.

Hybrigenics SA research on inhibitors of ubiquitin-specific proteases is at the forefront of innovation in the field of novel anticancer agents acting on the ubiquitin-proteasome system. Selective inhibitors of USP7 have been identified and protected by several patent applications. Their chemical optimization is ongoing.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

HYBRIGENICS

Press release

Hybrigenics is also the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life science, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics
Rémi Delansorne
CEO
Tel.: +33 (0)1 58 10 38 00
investors@hybrigenics.com

NewCap.
Financial communication
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
hybrigenics@newcap.fr